ClinicalTrials.Veeva

Menu

Glin3: Assessment of the Glycemic Responses to Nutritional Products (GLIN#3)

Nutricia logo

Nutricia

Status

Completed

Conditions

Glycemic Response

Treatments

Dietary Supplement: 2nd reference product series 2
Dietary Supplement: 1st concept product series 2
Dietary Supplement: 3rd reference product series 2
Dietary Supplement: 2nd concept product series 2
Dietary Supplement: 3rd concept product series 2
Dietary Supplement: 6th concept product series 2
Dietary Supplement: third reference product series 1
Dietary Supplement: 6th concept product series 1
Dietary Supplement: first concept product series 1
Dietary Supplement: 4th concept product seris 1
Dietary Supplement: third concept product series 1
Dietary Supplement: 1st reference product series 2
Dietary Supplement: first reference product series 1
Dietary Supplement: second reference product seies 1
Dietary Supplement: 5th concept product series 2
Dietary Supplement: 5th concept product series 1
Dietary Supplement: 4th concept product series 2
Dietary Supplement: second concept product series 1

Study type

Interventional

Funder types

Industry

Identifiers

NCT06215534
23REX0060928

Details and patient eligibility

About

This study assesses the glycemic responses to nutritional products. During a study visit fasted subjects will consume one serving of the reference product or the test product. Capillary blood samples will be taken at baseline and at several time-points over a 2-hr period. Several nutritional products will be tested over time.

Enrollment

12 patients

Sex

All

Ages

18 to 65 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Age ≥ 18 and ≤ 65 years
  • Body mass index (BMI) between 18.5 and 27 kg/m²

Exclusion criteria

  • Baseline fasting Glucose ≥6.1 at screening visit
  • Known history of gastrointestinal disease, bariatric surgery, AIDS, hepatitis, a history or presence of clinically important endocrine (including Type 1 or Type 2 diabetes mellitus), or any condition which might, in the opinion of the medical director either: 1) make participation dangerous to the subject or to others, or 2) affect the results.
  • Use of medications known to influence carbohydrate metabolism, gastrointestinal function or appetite, including, but not limited to adrenergic blockers, diuretics, thiazolidinediones, metformin and systemic corticosteroids within 4 weeks of the screening visit, or any medication which might, in the opinion of the medical director either: 1) make participation dangerous to the subject or to others, or 2) affect the results.
  • Major trauma or surgical event within 3 months of screening.
  • Known intolerance, sensitivity or allergy to test products.
  • Extreme dietary habits, as judged by the Investigator (i.e. Atkins diet, very high protein diets, etc.).
  • History of cancer in the prior two years, except for non-melanoma skin cancer.

Trial design

Primary purpose

Other

Allocation

Randomized

Interventional model

Crossover Assignment

Masking

None (Open label)

12 participants in 18 patient groups

arm 1
Other group
Description:
All subjects will receive all interventions during the trial. The order of the Nutritional products will be randomized.
Treatment:
Dietary Supplement: first reference product series 1
arm 2
Other group
Description:
All subjects will receive all interventions during the trial. The order of the Nutritional products will be randomized.
Treatment:
Dietary Supplement: second reference product seies 1
arm 3
Other group
Description:
All subjects will receive all interventions during the trial. The order of the Nutritional products will be randomized.
Treatment:
Dietary Supplement: third reference product series 1
arm 4
Other group
Description:
All subjects will receive all interventions during the trial. The order of the Nutritional products will be randomized.
Treatment:
Dietary Supplement: first concept product series 1
arm 5
Other group
Description:
All subjects will receive all interventions during the trial. The order of the Nutritional products will be randomized.
Treatment:
Dietary Supplement: second concept product series 1
arm 6
Other group
Description:
All subjects will receive all interventions during the trial. The order of the Nutritional products will be randomized.
Treatment:
Dietary Supplement: third concept product series 1
arm 7
Other group
Description:
All subjects will receive all interventions during the trial. The order of the Nutritional products will be randomized.
Treatment:
Dietary Supplement: 4th concept product seris 1
arm 8
Other group
Description:
All subjects will receive all interventions during the trial. The order of the Nutritional products will be randomized.
Treatment:
Dietary Supplement: 5th concept product series 1
arm 9
Other group
Description:
All subjects will receive all interventions during the trial. The order of the Nutritional products will be randomized.
Treatment:
Dietary Supplement: 6th concept product series 1
arm 10
Other group
Description:
All subjects will receive all interventions during the trial. The order of the Nutritional products will be randomized.
Treatment:
Dietary Supplement: 1st reference product series 2
arm 11
Other group
Description:
All subjects will receive all interventions during the trial. The order of the Nutritional products will be randomized.
Treatment:
Dietary Supplement: 2nd reference product series 2
arm 12
Other group
Description:
All subjects will receive all interventions during the trial. The order of the Nutritional products will be randomized.
Treatment:
Dietary Supplement: 3rd reference product series 2
arm 13
Other group
Description:
All subjects will receive all interventions during the trial. The order of the Nutritional products will be randomized.
Treatment:
Dietary Supplement: 1st concept product series 2
arm 14
Other group
Description:
All subjects will receive all interventions during the trial. The order of the Nutritional products will be randomized.
Treatment:
Dietary Supplement: 2nd concept product series 2
arm 15
Other group
Description:
All subjects will receive all interventions during the trial. The order of the Nutritional products will be randomized.
Treatment:
Dietary Supplement: 3rd concept product series 2
arm 16
Other group
Description:
All subjects will receive all interventions during the trial. The order of the Nutritional products will be randomized.
Treatment:
Dietary Supplement: 4th concept product series 2
arm 17
Other group
Description:
All subjects will receive all interventions during the trial. The order of the Nutritional products will be randomized.
Treatment:
Dietary Supplement: 5th concept product series 2
arm 18
Other group
Description:
All subjects will receive all interventions during the trial. The order of the Nutritional products will be randomized.
Treatment:
Dietary Supplement: 6th concept product series 2

Trial contacts and locations

1

Loading...

Central trial contact

danone nutricia research

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems